Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 15/20 | 0.36 |
| ▸ | MTOR | P42345 | 15/20 | 0.36 |
| ▸ | PDE2A | O00408 | 2/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | MAT2A | P31153 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.30 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25876299 | 0.90 | LRRK2 (0.36) | PIK3CAMTORPDE2APIK3CDMAT2A | |
| SCHEMBL25876239 | 0.89 | MAT2A (0.32) | PDE2AMAT2A | |
| SCHEMBL25875946 | 0.88 | MAT2A (0.40) | PIK3CAMTORMAT2A | |
| SCHEMBL25876280 | 0.87 | PDE1A (0.37) | MAT2A | |
| SCHEMBL25876083 | 0.87 | MERTK (0.35) | MAT2A | |
| SCHEMBL25876042 | 0.86 | MAT2A (0.33) | MAT2ALRRK2 | |
| SCHEMBL25875917 | 0.83 | PDE2A (0.40) | PIK3CAPDE2A | |
| SCHEMBL25876132 | 0.82 | PIK3CA (0.34) | PIK3CAMTOR | |
| SCHEMBL25875905 | 0.82 | KLKB1 (0.31) | — | |
| SCHEMBL25876052 | 0.80 | PDE9A (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234954-A1 | COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF | TYK MEDICINES, INC. (CN) | 2023-07-27 | — | — | US | disclosed |
| US-20230234954-A1 | COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF | TYK MEDICINES, INC. (CN) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234954-A1 | COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF | RET, ROR1, FGFR3 | PIK3CA 487/4885MTOR 390/4885PDE2A 1000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.